ARTICLE | Company News
Otsuka acquiring antibody play Visterra
July 13, 2018 7:58 PM UTC
Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) is acquiring antibody developer Visterra Inc. (Waltham, Mass.) for $430 million in cash, the companies said on July 11.
The deal gives Otsuka a pipeline based on Visterra's Hierotope platform, which is designed to target specific, highly networked epitopes believed to be important in the function of antigens. Otsuka said it is prioritizing platform-based R&D, including antibody development platforms, to make drug discovery more efficient...
BCIQ Target Profiles
Tumor necrosis factor (TNF) ligand superfamily member 13 (TNFSF13) (APRIL)